ReviewFrontiers in immunology2020
Nuclear Factor κB (NF-κB)-Mediated Inflammation in Multiple Sclerosis.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 137 citations in OpenAlex.
- Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.Frontiers in immunology · 2025Trial
- Integrative population genomics and tissue-specific expression profiling in cattle using whole-genome sequence resources.BMC genomics · 2026Article
- Supplementation of pectic oligosaccharide alleviates lipopolysaccharide-induced intestinal inflammatory damages and impairment of growth performance in broilers.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- S3I-201, a STAT3 Inhibitor, Inhibits Proinflammatory Mediator Signalling in CD19 and CD45R/B220 Cells in a Mouse Model of Multiple Sclerosis.Cellular and molecular neurobiology · 2026Article
- ATF6 ameliorates renal warm ischemia-reperfusion injury through FHL2-mediated NF-κB signaling pathway.iScience · 2026Article
- Genomic Impacts of Biological Exposures.Journal of developmental biology · 2026Review
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- 2'-deoxyinosine ameliorates multiple sclerosis through modulating Th1/Th2 and Th17/Treg cell balance with potential involvement of AMPK phosphorylation.Frontiers in pharmacology · 2026Article
- Shen-Ling-Bai-Zhu-San Mitigates Ulcerative Colitis by Enhancing Intestinal Barrier Integrity via the AhR-CYP1A1-NF-κB Signal Pathway.Combinatorial chemistry & high throughput screening · 2026Article
- Bingqing Gao Facilitates the Healing Process of Full-Thickness Skin Defects in Rat Wounds by Activating the PI3K/AKT Pathway.Combinatorial chemistry & high throughput screening · 2026Article
- Uncovering Potential Susceptibility Genes for Multiple Sclerosis-Induced Neuropathic Bladder: A Mendelian Randomization Analysis.Molecular neurobiology · 2025Article
- Relationship of S100 Proteins with Neuroinflammation.Biomolecules · 2025Review
- Multiomics integration prioritizes potential drug targets for multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients.European journal of neurology · 2025Article
- Exploring the therapeutic potential of nutraceutical compounds (Curcumin, Quercetin, Epa, Zinc, and Vitamin D) in managing Celiac disease: insights from cellular mechanisms.Molecular biology reports · 2025Article
- Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.Current issues in molecular biology · 2025Review
- Exosomal non-coding RNAs: gatekeepers of inflammation in autoimmune disease.Journal of inflammation (London, England) · 2025Review
- Novel serum biomarker associations with 7 Tesla MRI-defined cortical lesions, leptomeningeal enhancement, and deep gray matter volume in early multiple sclerosis.Scientific reports · 2025Article
- Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Hypoxic Neuroinflammation in the Pathogenesis of Multiple Sclerosis.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclear factor κB (NF-κB) signaling cascade has been implicating in a broad range of biological processes, including inflammation, cell proliferation, differentiation, and apoptosis. The past three decades have witnessed a great progress in understanding the impact of aberrant NF-κB regulation on human autoimmune and inflammatory disorders. In this review, we discuss how aberrant NF-κB activation contributes to multiple sclerosis, a typical inflammatory demyelinating disease of the central nervous system, and its involvement in developing potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.